Imunon Inc (IMNN)

$2.17 -0.34 (-13.55%)
Market Cap 43.68M
Revenue (ttm) 0.00
Net Income (ttm) -18.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,274,085
Avg Vol 12,893,042
Day's Range N/A - N/A
Shares Out 17.54M
Stochastic %K 77%
Beta 1.75
Analysts Strong Sell
Price Target $9.75

Latest News on IMNN

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 3, 2025, 8:05 AM EDT - 5 hours ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

Jun 2, 2025, 8:05 AM EDT - 1 day ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 27, 2025, 8:05 AM EDT - 7 days ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 6:59 PM EDT - 10 days ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 23, 2025, 8:05 AM EDT - 11 days ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 22, 2025, 5:20 PM EDT - 11 days ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 15, 2025, 8:05 AM EDT - 19 days ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 12:56 PM EDT - 22 days ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 8:00 AM EDT - 22 days ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 8, 2025, 8:05 AM EDT - 26 days ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 6, 2025, 8:05 AM EDT - 4 weeks ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

May 5, 2025, 8:00 AM EDT - 4 weeks ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Apr 21, 2025, 8:05 AM EDT - 6 weeks ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Mar 24, 2025, 8:00 AM EDT - 2 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:32 PM EST - 3 months ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 27, 2025, 8:05 AM EST - 3 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 26, 2025, 8:05 AM EST - 3 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 20, 2025, 8:30 AM EST - 3 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 19, 2025, 8:05 AM EST - 3 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

IMUNON Appoints Douglas V. Faller, M.D.

Feb 10, 2025, 8:05 AM EST - 4 months ago

IMUNON Appoints Douglas V. Faller, M.D.

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 19, 2024, 8:05 AM EST - 5 months ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Dec 10, 2024, 8:05 AM EST - 6 months ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Nov 25, 2024, 8:05 AM EST - 6 months ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 5:11 PM EST - 7 months ago

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Nov 7, 2024, 10:00 AM EST - 7 months ago

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 7, 2024, 8:05 AM EST - 7 months ago

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

Oct 31, 2024, 8:30 AM EDT - 7 months ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Oct 30, 2024, 9:05 AM EDT - 7 months ago

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 7, 2024, 8:05 AM EDT - 8 months ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

Sep 9, 2024, 4:06 PM EDT - 9 months ago

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

IMUNON to Host R&D Day on September 18th

Aug 28, 2024, 8:30 AM EDT - 9 months ago

IMUNON to Host R&D Day on September 18th

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 2:55 PM EDT - 10 months ago

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 14, 2024, 8:00 AM EDT - 10 months ago

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

Aug 7, 2024, 5:04 PM EDT - 10 months ago

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Jul 30, 2024, 1:07 PM EDT - 11 months ago

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Imunon's stock rockets after ovarian cancer treatment's positive trial results

Jul 30, 2024, 9:42 AM EDT - 11 months ago

Imunon's stock rockets after ovarian cancer treatment's positive trial results

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

Jul 30, 2024, 8:00 AM EDT - 11 months ago

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Jul 29, 2024, 4:05 PM EDT - 11 months ago

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

Jun 24, 2024, 8:30 AM EDT - 1 year ago

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

Jun 5, 2024, 8:30 AM EDT - 1 year ago

First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2024, 8:30 AM EDT - 1 year ago

Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript

May 13, 2024, 6:05 PM EDT - 1 year ago

Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

May 13, 2024, 9:00 AM EDT - 1 year ago

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

May 8, 2024, 8:00 AM EDT - 1 year ago

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

May 6, 2024, 11:00 AM EDT - 1 year ago

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101

Apr 18, 2024, 8:30 AM EDT - 1 year ago

IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101

IMUNON Reports Compliance with Nasdaq Listing Requirements

Apr 11, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports Compliance with Nasdaq Listing Requirements

Imunon, Inc. (IMNN) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 12:35 PM EDT - 1 year ago

Imunon, Inc. (IMNN) Q4 2023 Earnings Call Transcript

IMUNON Reports 2023 Financial Results and Provides Business Update

Mar 28, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports 2023 Financial Results and Provides Business Update